Agilent Technologies, Inc.
Agilent is executing well and FY26 is inflecting higher, but at $156.47 and just 4.4% below its 52-week high, the market is already paying up for a recovery that still needs to prove durable into FY27.
Agilent's operating picture is better than it was a year ago. The company just posted a strong Q3, with the CEO stating, "For the third quarter, Agilent reported $1.88 billion in revenue, growing 7.3% on a core basis and exceeding the high end of our guidance by 140 basis points." China was a real upside factor at +9% against a flat expectation, strategic pricing contributed roughly 200 bps, and management raised full-year expectations to $7.49B-$7.51B of revenue and $6.18-$6.21 of EPS. That is a real improvement in earnings power versus FY2025 EPS of $4.59, and the beat cadence has been solid with 7 beats in 8 quarters.
The problem is that the market has already rewarded that recovery. At $156.47, the stock is only 4.4% below its 52-week high, 18.9% above its 200-day average, and up 15.47% over the last three months. That leaves less room for error when valuation sits at 30.74x earnings and 5.99x sales. The P/E is below the peer average of 36.2x, but the P/S is above the peer average 5.0x, and Agilent's own factor profile is not screaming undiscovered growth, with Growth Potential at 43/100 and Innovation Investment at 26/100. This is a quality company, not an early-cycle mispricing.
The case now depends on three things. First, FY26 guidance needs to hold, especially the ex-refund EPS range of $6.12-$6.15. Second, management needs to convert favorable leading indicators, including book-to-bill above 1 for 10 straight quarters, into visible FY27 revenue and margin progression. Third, newer growth pieces need to matter, including Train C, where revenue generation starts next spring with a 6-8 quarter ramp, and pharma reshoring, where management said order benefits should build around year-end and become revenue in fiscal 2027 and beyond.
That setup supports patience, not aggression. The moat is credible and execution has improved, but the stock no longer offers enough valuation slack to absorb a slowdown in ATD, weaker diagnostics conversion, or persistent cost pressure. The right stance is to respect the better business trend while waiting for either a better price or stronger evidence that FY27 can carry the current multiple.
Quant call (HOLD) diverges from analyst consensus (Strong Buy: 14 buy / 1 hold / 0 sell) — resolve explicitly.
The big money is not in the buying or the selling, but in the waiting.
Forward earnings power has clearly improved, with FY26 EPS guided to $6.18-$6.21, which puts the stock at roughly 25x forward earnings versus a 30.74x trailing P/E. That is not excessive for a high-quality life sciences tools franchise, but it is not a bargain either given modest long-run growth and a Growth Potential score of 43/100. The moat still looks solid, built on installed instruments, regulated workflows, consumables, and service relationships, and it should remain intact over the next 3-5 years as pharma reshoring, replacement demand, and Train C add capacity. AI is more enabling than disruptive here, likely helping lab automation, workflow efficiency, and data interpretation rather than creating a step-change in Agilent's growth rate, so the case still hinges on steady execution, not a structural AI windfall.
- FY26 EPS guidance of $6.18-$6.21 implies meaningful earnings acceleration versus FY2025 EPS of $4.59, confirming an improving operating cycle.
- Q3 core revenue growth of 7.3% beat the high end of guidance by 140 bps, with China +9% and strategic pricing of about 200 bps supporting the raise.
- Valuation is no longer cheap enough to underwrite execution risk: P/E 30.74x, P/S 5.99x versus peer 5.0x, with the stock -4.4% from its 52-week high.
- Management raised FY26 guidance to $7.49B-$7.51B revenue and $6.18-$6.21 EPS, and the CEO said, "We now expect core growth of 5.8% to 6% for the full year."
- Execution has improved materially, with 7 beats in the last 8 quarters, including +8.7% EPS surprise on 2026-08-26 and +5.7% on 2026-05-27.
- Margins are recovering: Q3 operating margin ex tariff refunds was 27.2%, up 210 bps year over year, and Q3 EBITDA margin was 25.2% on $1.88B of revenue.
- Demand visibility is decent for a tools company, with book-to-bill above 1 for 10 straight quarters, Train C mechanically complete, and management expecting reshoring-related revenue to build in fiscal 2027 and beyond.
- The stock already reflects much of the rebound, trading at 30.74x earnings and 5.99x sales, above the peer 5.0x sales average and only modestly below the peer 36.2x P/E average despite weaker growth sub-score of 43/100.
- Trailing fundamentals are still muted: FY2025 revenue fell 0.9% and operating margin slipped to 22.7% from 22.9%, so the rerating leans heavily on forward delivery.
- Cash generation looks light relative to earnings and market value, with just $0.4B of FCF on $6.9B revenue and $44.2B market cap, while leverage sits at 2.15x debt/EBITDA.
- Some end markets remain uneven, with Q4 ATD flattish against a tough greater than 40% compare, diagnostics slightly below expectations, and persistent input pressure from memory-chip inflation and Middle East-related costs.
| Metric | Value | Context |
|---|---|---|
| Current price | $156.47 | Reference point for rating and quant target comparison |
| Quant price target | $154.78 | -1.1% vs current, Medium confidence, quant baseline HOLD |
| FY2025 revenue | $6.9B | -0.9% YoY, trailing base before FY26 rebound |
| FY2025 EPS | $4.59 | +2.4% YoY |
| FY2025 operating margin | 22.7% | Down from 22.9% in prior FY |
| FY26 guidance | Revenue $7.49B-$7.51B, EPS $6.18-$6.21 | Core revenue growth guided at 5.8%-6.0% |
| Q3 FY26 performance | $1.88B revenue, $0.47B EBITDA, 25.2% EBITDA margin | Core revenue +7.3%, China +9% |
| Valuation | P/E 30.74x, P/S 5.99x, P/B 5.99x | Peer avg P/E 36.2x, peer avg P/S 5.0x |
| Balance sheet | Debt/Equity 0.54, Debt/EBITDA 2.15x, Current ratio 2.05 | Total debt $3.9B |
| Free cash flow | $0.4B | Weak relative to $44.2B market cap |
| Quality and risk | Quality 61/100, Risk 41/100 | Moderate risk |
| 52-week position | Range $108.35-$163.75 | Current price is -4.4% vs high and 18.9% above 200-day average |
The biggest risk to a more positive stance is that the stock is pricing in a sustained recovery, yet valuation remains full at 30.74x earnings even as FY2025 revenue was still -0.9% YoY and FCF was only $0.4B.
The next catalyst is Q4/FY26 earnings on November 23, 2026, especially whether management can convert the current book-to-bill above 1 and China strength into a credible FY27 growth and margin framework.
Agilent posted a strong Q3 beat and raised FY26 guidance on broad-based momentum.
We now expect core growth of 5.8% to 6% for the full year.
On an ex tariff refund basis, fiscal year '26 earnings per share are now expected to be between $6.12 and $6.15. Including the net benefit of refunds received in Q3, earnings per share are expected to be between $6.18 and $6.21.
For the third quarter, Agilent reported $1.88 billion in revenue, growing 7.3% on a core basis and exceeding the high end of our guidance by 140 basis points.
The updated full year guidance implies that reported revenue in the fourth quarter will be in the range of $1.98 billion to $2 billion. Together, EPS is expected to be in the range of $1.71 to $1.74, representing growth of 8% to 9%.
We continue to expect more meaningful order benefit from pharma reshoring around year-end, with revenue contributions building in fiscal 2027 and beyond.
Agilent is a good business in a better operating phase, but the stock is no longer mispriced. HOLD, Medium conviction fits the setup because the recovery is visible while the upside from here is not, especially against the quant target of $154.78. A more positive view would need either a lower entry point or stronger proof that the current $6.18-$6.21 FY26 EPS guide can step up again in FY27. A more negative view would require evidence that China, pricing, or book-to-bill momentum is fading. For now, the business merits respect and the stock merits discipline.
≣ Full research note tap to expand
Executive Summary
HOLD, Medium conviction. A rates HOLD, Medium conviction. The business is improving, with FY26 revenue guided to $7.49B-$7.51B and EPS to $6.18-$6.21, supported by 7.3% core growth in Q3, book-to-bill above 1 for the 10th straight quarter, and better China demand. The issue is price: the quant price target is $154.78, essentially flat to slightly down from $156.47, while the stock has already rallied 15.47% in 3 months and sits 18.9% above its 200-day average.
Investment Thesis
Agilent's operating picture is better than it was a year ago. The company just posted a strong Q3, with the CEO stating, "For the third quarter, Agilent reported $1.88 billion in revenue, growing 7.3% on a core basis and exceeding the high end of our guidance by 140 basis points." China was a real upside factor at +9% against a flat expectation, strategic pricing contributed roughly 200 bps, and management raised full-year expectations to $7.49B-$7.51B of revenue and $6.18-$6.21 of EPS. That is a real improvement in earnings power versus FY2025 EPS of $4.59, and the beat cadence has been solid with 7 beats in 8 quarters.
The problem is that the market has already rewarded that recovery. At $156.47, the stock is only 4.4% below its 52-week high, 18.9% above its 200-day average, and up 15.47% over the last three months. That leaves less room for error when valuation sits at 30.74x earnings and 5.99x sales. The P/E is below the peer average of 36.2x, but the P/S is above the peer average 5.0x, and Agilent's own factor profile is not screaming undiscovered growth, with Growth Potential at 43/100 and Innovation Investment at 26/100. This is a quality company, not an early-cycle mispricing.
The case now depends on three things. First, FY26 guidance needs to hold, especially the ex-refund EPS range of $6.12-$6.15. Second, management needs to convert favorable leading indicators, including book-to-bill above 1 for 10 straight quarters, into visible FY27 revenue and margin progression. Third, newer growth pieces need to matter, including Train C, where revenue generation starts next spring with a 6-8 quarter ramp, and pharma reshoring, where management said order benefits should build around year-end and become revenue in fiscal 2027 and beyond.
That setup supports patience, not aggression. The moat is credible and execution has improved, but the stock no longer offers enough valuation slack to absorb a slowdown in ATD, weaker diagnostics conversion, or persistent cost pressure. The right stance is to respect the better business trend while waiting for either a better price or stronger evidence that FY27 can carry the current multiple.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Current price | $156.47 | Reference point for rating and quant target comparison |
| Quant price target | $154.78 | -1.1% vs current, Medium confidence, quant baseline HOLD |
| FY2025 revenue | $6.9B | -0.9% YoY, trailing base before FY26 rebound |
| FY2025 EPS | $4.59 | +2.4% YoY |
| FY2025 operating margin | 22.7% | Down from 22.9% in prior FY |
| FY26 guidance | Revenue $7.49B-$7.51B, EPS $6.18-$6.21 | Core revenue growth guided at 5.8%-6.0% |
| Q3 FY26 performance | $1.88B revenue, $0.47B EBITDA, 25.2% EBITDA margin | Core revenue +7.3%, China +9% |
| Valuation | P/E 30.74x, P/S 5.99x, P/B 5.99x | Peer avg P/E 36.2x, peer avg P/S 5.0x |
| Balance sheet | Debt/Equity 0.54, Debt/EBITDA 2.15x, Current ratio 2.05 | Total debt $3.9B |
| Free cash flow | $0.4B | Weak relative to $44.2B market cap |
| Quality and risk | Quality 61/100, Risk 41/100 | Moderate risk |
| 52-week position | Range $108.35-$163.75 | Current price is -4.4% vs high and 18.9% above 200-day average |
Financial Strength
Agilent's balance sheet is sound enough for the cycle it is in, but it is not pristine enough to ignore valuation. Leverage at 2.15x debt/EBITDA and 0.54 debt/equity is manageable, and the 2.05 current ratio supports operational flexibility. Profitability remains healthy, with 19.3% net margin and a clear recovery in Q3 operating margin ex refunds, but the weak spot is cash conversion, with just $0.4B of FCF against $6.9B of FY2025 revenue. That makes the business financially stable, yet it also limits the case for paying a premium multiple unless margin gains and conversion continue to improve through FY27.
Competitive Position
Agilent's moat comes from embedded instruments, validated workflows, switching costs in regulated labs, and recurring pull-through from consumables and service. Those advantages are real in pharma, diagnostics, and applied markets, and they help explain why the company can push about 200 bps of strategic pricing while keeping book-to-bill above 1 for 10 straight quarters. The moat looks durable over the next few years, especially as Train C expands capacity and reshoring supports demand. The main limitation is that this is still a steady compounder rather than a category creator, so moat durability does not automatically justify any price.
Management & Guidance
Management has earned a fair degree of credibility. The latest call carried an 84/100 calibrated sentiment score, and the guidance raise was backed by operating evidence, not just tone. The CEO said, "We now expect core growth of 5.8% to 6% for the full year." The CFO added, "On an ex tariff refund basis, fiscal year '26 earnings per share are now expected to be between $6.12 and $6.15. Including the net benefit of refunds received in Q3, earnings per share are expected to be between $6.18 and $6.21." That guidance deserves respect because Agilent has beaten in 7 of the last 8 quarters, but credibility is not the same as certainty, especially with Q4 ATD flattish, diagnostics conversion lagging, and some cost pressure persisting.
Bull Case
- Management raised FY26 guidance to $7.49B-$7.51B revenue and $6.18-$6.21 EPS, and the CEO said, "We now expect core growth of 5.8% to 6% for the full year."
- Execution has improved materially, with 7 beats in the last 8 quarters, including +8.7% EPS surprise on 2026-08-26 and +5.7% on 2026-05-27.
- Margins are recovering: Q3 operating margin ex tariff refunds was 27.2%, up 210 bps year over year, and Q3 EBITDA margin was 25.2% on $1.88B of revenue.
- Demand visibility is decent for a tools company, with book-to-bill above 1 for 10 straight quarters, Train C mechanically complete, and management expecting reshoring-related revenue to build in fiscal 2027 and beyond.
Bear Case
- The stock already reflects much of the rebound, trading at 30.74x earnings and 5.99x sales, above the peer 5.0x sales average and only modestly below the peer 36.2x P/E average despite weaker growth sub-score of 43/100.
- Trailing fundamentals are still muted: FY2025 revenue fell 0.9% and operating margin slipped to 22.7% from 22.9%, so the rerating leans heavily on forward delivery.
- Cash generation looks light relative to earnings and market value, with just $0.4B of FCF on $6.9B revenue and $44.2B market cap, while leverage sits at 2.15x debt/EBITDA.
- Some end markets remain uneven, with Q4 ATD flattish against a tough greater than 40% compare, diagnostics slightly below expectations, and persistent input pressure from memory-chip inflation and Middle East-related costs.
Valuation & Price Target
Engine price target $154.78 (-1.1% vs current), Medium confidence.
- P/E Multiple: $185.73 (28% weight)
- P/S Multiple: $123 (20% weight)
- Quality-adjusted: $170.24 (20% weight)
- DCF: $67.64 (6% weight)
The HOLD rating aligns with the quant baseline HOLD and its $154.78 price target, which is -1.1% versus the current $156.47. A divergence to BUY would require either cheaper entry or clearer proof that FY26 guidance of $6.18-$6.21 can compound into stronger FY27 earnings without margin giveback, especially since the stock is already -4.4% from its high after a 15.47% 3-month run. Sell-side consensus is Strong Buy (14 buy / 1 hold / 0 sell), but that is low-signal context here because the stock's current setup is more about valuation versus realized forward earnings than broad enthusiasm about quality.
Risk Assessment
Risk score 41/100 (Moderate). The biggest risk to a more positive stance is that the stock is pricing in a sustained recovery, yet valuation remains full at 30.74x earnings even as FY2025 revenue was still -0.9% YoY and FCF was only $0.4B.
The Bottom Line
Agilent is a good business in a better operating phase, but the stock is no longer mispriced. HOLD, Medium conviction fits the setup because the recovery is visible while the upside from here is not, especially against the quant target of $154.78. A more positive view would need either a lower entry point or stronger proof that the current $6.18-$6.21 FY26 EPS guide can step up again in FY27. A more negative view would require evidence that China, pricing, or book-to-bill momentum is fading. For now, the business merits respect and the stock merits discipline.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr